BioEcho Life Sciences was only founded in 2016, and just six years later the Cologne-based company is already expanding into the world's most important market for biotechnology with its subsidiary BioEcho Life Sciences Inc. The rapid growth was also favored by the Corona pandemic and the resulting PCR tests.
Dr. Markus Müller, CEO and founder, emphasizes the added value of the expansion: "The U.S. market is a leader in biotechnology, accounting for about 60 percent of global sales of biotech products. Customer feedback from the U.S. can be a indicator for new trends, new technologies and new market applications. Entering the U.S. market with its own subsidiary allows BioEcho to be close to its customers and significantly shorten delivery times."
More than 60 employees now work for BioEcho. As a solution provider for the extraction and analysis of nucleic acids, they have developed a technology that enables DNA and RNA extraction in just one step. In addition, plastic waste can be reduced by up to 70 percent. Now the attractive North American market is to be served with the product range of the biotech company from NRW.
Operationally, the new Boston office has been operational since September 1. General Manager Lydia Willing adds, "We will offer a comprehensive portfolio of BioEcho products in the U.S. and be able to address specific customer needs in the area of nucleic acid research."